Skip to main content

Xenon Pharmaceuticals Inc.

XENE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001582313

In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 2 open-market purchases and 1 sale; 285 institutions reported holding it in 13F filings for Q3 2026, worth $3.76B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$3.71B
Insider buysLast 90 days, $1.68M in total
2
Insider sellsLast 90 days, $425.8K in total
1
13F holdersQ3 2026, −25 vs. previous quarter
285
13F valueReported value at the end of Q3 2026
$3.76B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$7.50M
No comparable prior period
Net income, FY2025
-$345.9M
No comparable prior period
Free cash flow, FY2025
-$279.9M
No comparable prior period
Revenue, Q3 FY2026
$0
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $345.9M (4612.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
7.36M
Shares sold short
Change
+14.8K
+0.2% vs. previous
Days to cover
6.36
At average daily volume

Superinvestors holding XENE, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding XENE at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Xenon Pharmaceuticals Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 1, 2026 (view filing)9:20 AM ETSep 301 dayKelly Thomas PatrickChief Financial OfficerPPurchase+15.0K$37.32+$559.7KNew position15.0K after
Oct 1, 2026 (view filing)9:19 AM ETSep 301 dayMortimer IanPRESIDENT & CEOPPurchase+30.0K$37.38+$1.12M+150.6%49.9K after
Aug 31, 2026 (view filing)9:59 PM ETAug 283 daysKenney Christopher JohnChief Medical OfficerSSale−7.07K$60.25−$425.8K−100.0%2 after2 lots10b5-1
Aug 13, 2026 (view filing)4:33 PM ETAug 112 daysGannon StevenDirectorSSale−10.0K$64.06−$640.5K−84.2%1.87K after
Jun 8, 2026 (view filing)Jun 53 daysPatou GaryDirectorSSale−1.32K$53.14−$70.3K−5.0%24.9K after10b5-1
Jun 8, 2026 (view filing)Jun 53 daysCannon GillianDirectorSSale−1.19K$53.14−$63.2K−45.0%1.46K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayKenney Christopher JohnChief Medical OfficerSSale−1.41K$55.23−$77.9K−16.6%7.07K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayDiFabio AndreaChief Legal OfficerSSale−1.34K$55.23−$74.1K−15.5%7.30K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayMortimer IanPRESIDENT & CEOSSale−7.31K$55.23−$403.6K−26.8%19.9K after10b5-1
Mar 11, 2026 (view filing)Mar 101 dayKenney Christopher JohnChief Medical OfficerSSale−2.77K$60.11−$166.6K−36.9%4.73K after10b5-1

Top 10 13F holders, Q3 2026

See all 285 holders

The largest institutional positions in Xenon Pharmaceuticals Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding XENE in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC11,554,454$429.7M0.02%+1,906,456+19.8%Added
T. Rowe Price Investment Management, Inc.7,896,803$293.7M0.21%+5,728,222+264.1%Added
BlackRock, Inc.7,710,413$286.8M0.00%+187,931+2.5%Added
Avoro Capital Advisors LLC5,500,000$204.5M2.11%−277,777−4.8%Reduced
Polar Capital Holdings Plc5,022,084$186.8M0.52%+451,528+9.9%Added
Janus Henderson Group PLC4,002,869$148.8M0.06%+4,002,869New
Driehaus Capital Management LLC3,557,546$132.3M0.92%−861,011−19.5%Reduced
Price T Rowe Associates Inc3,178,798$118.2M0.01%−69,421−2.1%Reduced
Capital International Investors2,359,559$87.8M0.02%−2,080−0.1%Reduced
State Street Corp2,057,284$76.5M0.00%+87,655+4.5%Added

Holders of 5% or more of XENE

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xenon Pharmaceuticals Inc..

Largest holders of XENE from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A11.50%11.1M shares+1.20 ppfrom 10.30%Feb 8, 202110 filingsNov 5, 2026SEC
T. Rowe Price Investment Management, Inc.13G/A10.30%10.0M shares+2.10 ppfrom 8.20%Nov 6, 20262 filingsNov 6, 2026SEC
Avoro Capital Advisors LLC13G/A6.26%5.78M shares–Feb 12, 20215 filingsMay 15, 2026SEC
BlackRock, Inc.13G6.20%4.76M sharesNewJul 17, 20251 filingJul 17, 2025SEC
Polar Capital Holdings Plc13G5.19%5.02M sharesNewNov 16, 20261 filingNov 16, 2026SEC